Display options
Cite
Norouzian H, Gholami M, Shakib P, et al. Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran. Int J High Risk Behav Addict. 2016;5(1):e25028doi: 10.5812/ijhrba.25028.
Norouzian, H., Gholami, M., Shakib, P., Goudarzi, G., Ghobadian Diali, H., & Rezvani, A. (2016). Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran. International journal of high risk behaviors & addiction, 5(1), e25028. https://doi.org/10.5812/ijhrba.25028
Norouzian, Hossein, et al. "Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran." International journal of high risk behaviors & addiction vol. 5,1 (2016): e25028. doi: https://doi.org/10.5812/ijhrba.25028
Norouzian H, Gholami M, Shakib P, Goudarzi G, Ghobadian Diali H, Rezvani A. Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran. Int J High Risk Behav Addict. 2016 Jan 18;5(1):e25028. doi: 10.5812/ijhrba.25028. eCollection 2016 Mar. PMID: 27162762; PMCID: PMC4859996.
Copy Download .nbib Format: NLM
Share it on

Int J High Risk Behav Addict. 2016 Jan 18;5(1):e25028. doi: 10.5812/ijhrba.25028. eCollection 2016 Mar.

Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran.

International journal of high risk behaviors & addiction

Hossein Norouzian, Mohammadreza Gholami, Pegah Shakib, Gholamreza Goudarzi, Hamze Ghobadian Diali, Azam Rezvani

Affiliations

  1. Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, IR Iran.
  2. Razi Vaccine Serum Research Institute, Virology Department, Karaj, IR Iran.
  3. Deputy of Health Services, Lorestan University of Medical Sciences, Khorramabad, IR Iran.

PMID: 27162762 PMCID: PMC4859996 DOI: 10.5812/ijhrba.25028

Abstract

BACKGROUND: Hepatitis C is an infectious disease caused by blood-borne pathogen, hepatitis C virus (HCV).

OBJECTIVES: The purpose of this study was to investigate the prevalence of HCV infection and associated risk factors among addicts in drug treatment centers in Lorestan Province, Iran.

PATIENTS AND METHODS: A cross-sectional sero-behavioral survey was given to drug addicts in the drug treatment centers of Khorramabad, Lorestan Province, Iran during June 2012 - March 2013. Drug addicts were interviewed using a standard questionnaire including demographic, imprisonment history, and HCV-related risk behavior items. Thereafter, the sera drawn from the participants were tested for anti-HCV antibody (Ab), anti-human immunodeficiency virus (HIV) Ab, and hepatitis B surface antigen (HBsAg).

RESULTS: The mean age of the cohorts was 31.7. Up to 60.2% of drug users had educational levels less than high school, 67.5% were self-employed, and 32.5% were office workers. The mean duration of drug injection was 6.8 years. Statistical analyses indicated that the prevalence of HCV among drug addicts was positively associated with age, past incarceration, drug injection history, the duration of drug use, and tattooing. In addition, 16.23% of volunteers were HCV-positive. Of those infected with HCV, 1.10% was co-infected with HBV, 2.95% were positive for HIV, and 0.36% of HCV-positive cases were infected with all three viruses.

CONCLUSIONS: The high prevalence of HCV infection among this group implies a high rate of transmission and exposure to the risk of serious diseases. It is important that the high prevalence of HCV infection be taken into consideration to control further transmission of this infection.

Keywords: Hepatitis C Virus; Prevalence; Risk Factors; Substance Abuse Treatment Centers

References

  1. World J Gastroenterol. 2005 Jul 14;11(26):4085-9 - PubMed
  2. Transfusion. 2009 Oct;49(10):2214-20 - PubMed
  3. East Mediterr Health J. 2007 Mar-Apr;13(2):250-6 - PubMed
  4. Harm Reduct J. 2006 Mar 18;3:12 - PubMed
  5. J Epidemiol Community Health. 2001 Oct;55(10):766-7 - PubMed
  6. Epidemiol Infect. 2004 Jun;132(3):409-15 - PubMed
  7. Harm Reduct J. 2006 Jan 24;3:2 - PubMed
  8. J Viral Hepat. 2000 Jan;7(1):30-5 - PubMed
  9. J Med Virol. 2005 Jul;76(3):311-7 - PubMed
  10. Hemodial Int. 2010 Jul;14(3):253-62 - PubMed
  11. Epidemiol Infect. 2001 Dec;127(3):475-84 - PubMed
  12. Rev Saude Publica. 2000 Oct;34(5):431-6 - PubMed
  13. West J Med. 1992 Jan;156(1):30-5 - PubMed
  14. Braz J Infect Dis. 2009 Oct;13(5):356-8 - PubMed
  15. J Urban Health. 2009 Nov;86(6):902-8 - PubMed
  16. World J Gastroenterol. 2006 Aug 14;12(30):4884-7 - PubMed
  17. Ann Neurol. 2005 Jul;58(1):96-107 - PubMed
  18. J Urban Health. 2003 Mar;80(1):137-46 - PubMed
  19. Sex Transm Infect. 2006 Jun;82 Suppl 3:iii10-17 - PubMed
  20. Mutat Res. 2000 Apr;462(2-3):381-93 - PubMed
  21. Clin Infect Dis. 2003 Jul 1;37(1):33-40 - PubMed
  22. J Gastroenterol Hepatol. 2002 Oct;17(10):1092-7 - PubMed
  23. Int J Drug Policy. 2007 Oct;18(5):359-63 - PubMed
  24. J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):422-31 - PubMed

Publication Types